POAI
Price
$1.68
Change
-$0.06 (-3.45%)
Updated
May 16, 6:59 PM EST
SRDX
Price
$34.08
Change
+$0.52 (+1.55%)
Updated
May 16, 6:59 PM EST
75 days until earnings call
Ad is loading...

POAI vs SRDX

Header iconPOAI vs SRDX Comparison
Open Charts POAI vs SRDXBanner chart's image
Predictive Oncology
Price$1.68
Change-$0.06 (-3.45%)
Volume$16.8K
CapitalizationN/A
Surmodics
Price$34.08
Change+$0.52 (+1.55%)
Volume$14.05K
CapitalizationN/A
View a ticker or compare two or three
POAI vs SRDX Comparison Chart

Loading...

POAIDaily Signal changed days agoGain/Loss if shorted
 
Show more...
SRDXDaily Signal changed days agoGain/Loss if shorted
 
Show more...
VS
POAI vs. SRDX commentary
May 17, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is POAI is a Hold and SRDX is a StrongBuy.

COMPARISON
Comparison
May 17, 2024
Stock price -- (POAI: $1.74 vs. SRDX: $33.56)
Brand notoriety: POAI and SRDX are both not notable
Both companies represent the Medical Specialties industry
Current volume relative to the 65-day Moving Average: POAI: 25% vs. SRDX: 212%
Market capitalization -- POAI: $9.22M vs. SRDX: $397.04M
POAI [@Medical Specialties] is valued at $9.22M. SRDX’s [@Medical Specialties] market capitalization is $397.04M. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Medical Specialties] industry is $7.47B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

POAI’s FA Score shows that 1 FA rating(s) are green whileSRDX’s FA Score has 0 green FA rating(s).

  • POAI’s FA Score: 1 green, 4 red.
  • SRDX’s FA Score: 0 green, 5 red.
According to our system of comparison, POAI is a better buy in the long-term than SRDX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

POAI’s TA Score shows that 3 TA indicator(s) are bullish while SRDX’s TA Score has 4 bullish TA indicator(s).

  • POAI’s TA Score: 3 bullish, 4 bearish.
  • SRDX’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, POAI is a better buy in the short-term than SRDX.

Price Growth

POAI (@Medical Specialties) experienced а 0.00% price change this week, while SRDX (@Medical Specialties) price change was +6.24% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was +2.02%. For the same industry, the average monthly price growth was +4.43%, and the average quarterly price growth was +17.15%.

Reported Earning Dates

POAI is expected to report earnings on May 17, 2023.

SRDX is expected to report earnings on Jul 31, 2024.

Industries' Descriptions

@Medical Specialties (+2.02% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
A.I.dvisor published
a Summary for POAI with price predictions.
OPEN
A.I.dvisor published
a Summary for SRDX with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
SRDX($397M) has a higher market cap than POAI($9.22M). SRDX YTD gains are higher at: -7.675 vs. POAI (-47.112). SRDX has higher annual earnings (EBITDA): 22.1M vs. POAI (-13.93M). SRDX has more cash in the bank: 35.2M vs. POAI (11.9M). POAI has less debt than SRDX: POAI (3.16M) vs SRDX (33.9M). SRDX has higher revenues than POAI: SRDX (138M) vs POAI (1.81M).
POAISRDXPOAI / SRDX
Capitalization9.22M397M2%
EBITDA-13.93M22.1M-63%
Gain YTD-47.112-7.675614%
P/E RatioN/A71.51-
Revenue1.81M138M1%
Total Cash11.9M35.2M34%
Total Debt3.16M33.9M9%
FUNDAMENTALS RATINGS
POAI vs SRDX: Fundamental Ratings
POAI
SRDX
OUTLOOK RATING
1..100
5015
VALUATION
overvalued / fair valued / undervalued
1..100
29
Undervalued
90
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9885
PRICE GROWTH RATING
1..100
6440
P/E GROWTH RATING
1..100
10095
SEASONALITY SCORE
1..100
5085

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

POAI's Valuation (29) in the null industry is somewhat better than the same rating for SRDX (90) in the Medical Specialties industry. This means that POAI’s stock grew somewhat faster than SRDX’s over the last 12 months.

POAI's Profit vs Risk Rating (100) in the null industry is in the same range as SRDX (100) in the Medical Specialties industry. This means that POAI’s stock grew similarly to SRDX’s over the last 12 months.

SRDX's SMR Rating (85) in the Medical Specialties industry is in the same range as POAI (98) in the null industry. This means that SRDX’s stock grew similarly to POAI’s over the last 12 months.

SRDX's Price Growth Rating (40) in the Medical Specialties industry is in the same range as POAI (64) in the null industry. This means that SRDX’s stock grew similarly to POAI’s over the last 12 months.

SRDX's P/E Growth Rating (95) in the Medical Specialties industry is in the same range as POAI (100) in the null industry. This means that SRDX’s stock grew similarly to POAI’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
POAISRDX
RSI
ODDS (%)
Bullish Trend 1 day ago
80%
Bearish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
77%
Momentum
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
73%
MACD
ODDS (%)
Bullish Trend 1 day ago
80%
Bullish Trend 1 day ago
65%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
76%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 1 day ago
71%
Advances
ODDS (%)
Bullish Trend 3 days ago
84%
Bullish Trend 1 day ago
72%
Declines
ODDS (%)
Bearish Trend 10 days ago
90%
Bearish Trend 9 days ago
73%
BollingerBands
ODDS (%)
N/A
Bearish Trend 1 day ago
76%
Aroon
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
67%
View a ticker or compare two or three
Ad is loading...
POAIDaily Signal changed days agoGain/Loss if shorted
 
Show more...
SRDXDaily Signal changed days agoGain/Loss if shorted
 
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
JATIX63.171.37
+2.22%
Janus Henderson Glb Tech and Innovt I
CWSGX15.910.27
+1.73%
Carillon Chartwell Small Cap Growth Fund
TADFX8.160.09
+1.12%
Transamerica Sustainable Equity Inc R6
JFEIX34.660.36
+1.05%
JPMorgan Europe Dynamic L
NWKCX84.400.88
+1.05%
Nationwide Geneva Small Cap Gr R6

SRDX and

Correlation & Price change

A.I.dvisor indicates that over the last year, SRDX has been loosely correlated with LIVN. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if SRDX jumps, then LIVN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SRDX
1D Price
Change %
SRDX100%
+1.70%
LIVN - SRDX
40%
Loosely correlated
+2.88%
RVTY - SRDX
34%
Loosely correlated
+0.73%
SNN - SRDX
34%
Loosely correlated
-0.23%
KIDS - SRDX
34%
Loosely correlated
+0.16%
TMDX - SRDX
32%
Poorly correlated
+2.79%
More